No Data
No Data
Lineage Cell Therapeutics Price Target Cut to $3.00/Share From $4.00 by B. Riley Securities
Optimistic Outlook for Lineage Cell Therapeutics: Buy Rating Supported by Financial Stability and Strategic Developments
Craig-Hallum Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Cuts Target Price to $3
Lineage Cell Therapeutics Faces Uncertainty Amid New U.S. Administration's Policies
Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics Price Target Maintained With a $2.00/Share by D. Boral Capital